

GUB-UCN2

# High quality weight loss with Once weekly UCN2 analogues




SCIENCE OF CERTAINTY


# Substantial weight loss with today's pharmacotherapy



## Body weight loss



## Composition of weight loss



Lean mass accounts for 20-40 % of the weight lost  
Weight regained is mainly fat

# Time to focus on healthy weight loss

Treatment paradigm for future obesity treatment




Maximize loss of fat mass



While preserving/increasing lean mass




With potential cardiorenal upside



# Selective long-acting UCN2 analogues

Ready for development

## Selective receptor profile



## Excellent physical and chemical stability:

- + No amyloid fibril formation
- + High chemical stability
- + High solubility

## Pharmacokinetics:

- + Allometric scaling from data in mouse, rat and minipig **support once-weekly dosing in humans**

# Improved metabolic parameters with cardiorenal upside



Pre-clinical data: (GUB-UCN2)

**Fat mass loss**  
**Lean mass increase**  
**Improved glucose homeostasis**

The first panel contains three circular icons: a light blue circle with a white scale icon, a yellow circle with a white pancreas icon, and a dark blue circle with a white muscle icon.

**'healthy weight loss'**

**Improved kidney  
function**




**Improved heart/  
cardiovascular function**




# GUB-UCN2 increases lean mass and decreases fat mass dose-dependently in DIO rats




## Transient body weight loss



## Increased lean mass



## Decreased fat mass




### Key takeaways

- GUB-UCN2 in diet obese rats induces a dose dependent increase in lean mass accompanied by a decrease in fat mass


# GUB-UCN2 eliminates lean mass loss induced by other anti-obesity agents in DIO rats




## Sustained body weight



## Increased lean mass



## Decreased fat mass



**Key takeaways**

- GUB-UCN2 rescues lean mass loss and improves fat mass loss in obese rats with an Amylin (Cagrilintide) or a GLP-1R agonist (Semaglutide).

# Thank you for your attention

## Gubra A/S

Hørsholm Kongevej 11B  
2970 Hørsholm  
Denmark

Phone: +45 3152 2650



[www.gubra.dk](http://www.gubra.dk)

Let's stay connected

